A detailed history of Morgan Stanley transactions in Profound Medical Corp. stock. As of the latest transaction made, Morgan Stanley holds 4,534 shares of PROF stock, worth $34,322. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,534
Previous 4,534 -0.0%
Holding current value
$34,322
Previous $38,000 5.26%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Aug 16, 2024

SELL
$7.3 - $9.46 $14,432 - $18,702
-1,977 Reduced 30.36%
4,534 $38,000
Q1 2024

May 15, 2024

SELL
$7.3 - $9.46 $14,432 - $18,702
-1,977 Reduced 30.36%
4,534 $38,000
Q4 2023

Aug 16, 2024

BUY
$7.85 - $11.18 $15,519 - $22,102
1,977 Added 43.6%
6,511 $55,000
Q4 2023

Feb 13, 2024

SELL
$7.85 - $11.18 $9,600 - $13,673
-1,223 Reduced 15.81%
6,511 $55,000
Q3 2023

Nov 15, 2023

BUY
$7.91 - $13.27 $12,656 - $21,232
1,600 Added 26.08%
7,734 $78,000
Q2 2023

Aug 14, 2023

BUY
$9.27 - $14.88 $9,251 - $14,850
998 Added 19.43%
6,134 $79,000
Q1 2023

May 15, 2023

SELL
$8.85 - $13.27 $12,735 - $19,095
-1,439 Reduced 21.89%
5,136 $47,000
Q4 2022

Feb 14, 2023

SELL
$3.18 - $10.91 $2,057 - $7,058
-647 Reduced 8.96%
6,575 $71,000
Q3 2022

Nov 14, 2022

BUY
$3.99 - $9.3 $1,496 - $3,487
375 Added 5.48%
7,222 $29,000
Q2 2022

Oct 27, 2022

SELL
$6.34 - $9.53 $7,430 - $11,169
-1,172 Reduced 14.62%
6,847 $50,000
Q2 2022

Aug 15, 2022

SELL
$6.34 - $9.53 $7,430 - $11,169
-1,172 Reduced 14.62%
6,847 $50,000
Q1 2022

Oct 27, 2022

BUY
$8.16 - $11.33 $9,563 - $13,278
1,172 Added 17.12%
8,019 $72,000
Q1 2022

May 13, 2022

SELL
$8.16 - $11.33 $6,120 - $8,497
-750 Reduced 8.55%
8,019 $72,000
Q4 2021

Feb 14, 2022

BUY
$10.38 - $15.2 $8,594 - $12,585
828 Added 10.43%
8,769 $99,000
Q3 2021

Nov 15, 2021

BUY
$13.6 - $17.88 $107,997 - $141,985
7,941 New
7,941 $116,000

Others Institutions Holding PROF

About Profound Medical Corp.


  • Ticker PROF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 20,851,300
  • Market Cap $158M
  • Description
  • Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for...
More about PROF
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.